<1xbet 한국ad prefix="og: http://ogp.me/ns# fb: http://ogp.me/ns/fb# article: http://ogp.me/ns/article#"> 1xbet 한국
  1. HOME
  2. About Otsuka
  3. News Releases
  4. 2016
  5. Otsuka and Medimetriks Sign Licensing Agreement for Development and Commercialization of OPA-15406 in t1xbet 한국 U.S. for Atopic Dermatitis

Otsuka Pharmaceuti1xbet 한국l Co., Ltd.

Pharmaceuti1xbet 한국ls
February 9, 2016

Otsuka and Medimetriks Sign Licensing Agreement for Development and Commercialization of OPA-15406 in t1xbet 한국 U.S. for Atopic Dermatitis

Otsuka Pharmaceutical Co., Ltd. and Medimetriks Pharmaceuticals, Inc. (based in Fairfield, New Jersey, U.S.) announced that t1xbet 한국y entered into a licensing agreement on February 8 (U.S. date).
T1xbet 한국 agreement provides Medimetriks, a company specializing in t1xbet 한국 dermatology market, with development, marketing and manufacturing rights to OPA-15406 in t1xbet 한국 United State. Otsuka receives a USD 22 million lump sum payment (approximately Yen 2.5 billion) and additional milestones through regulatory approval.
Otsuka discovered t1xbet 한국 molecule OPA-15406, a new t1xbet 한국rapeutic agent in development for atopic dermatitis. OPA-15046 has inhibitory effects on phosphodiesterase IV (PDE-4).

Previous
Next
Latest Pharmaceuti1xbet 한국l Business related News Releases
Most Recent Releases